Pacific trial, a phase III clinical trial on unresectable NSCLC patients, demonstrated longer PFS (17.2 vs 5.6 months), OS (28.3 vs 16.2 months) and a higher ORR (30% vs 17.8%) in patients treated with anti-PD-L1 Duvalumab within 1-14 days of completing chemoradiotherapy (217). Here, CD274 is linked to non-small cell lung carcinoma.